Results 221 to 230 of about 349,749 (268)

Fulminant Type 1 Diabetes Mellitus With Concomitant Coxsackievirus B6 Antibody Elevation and RNA‐Based COVID‐19 Vaccination: A Case Report and Review of the Literature

Clinical Case Reports, Volume 13, Issue 4, April 2025.
ABSTRACT Fulminant type 1 diabetes is a rare but severe condition that can develop rapidly, often in association with viral infections. In this case, coxsackievirus B6 antibody levels were elevated after disease onset, though its significance remains unclear.
Hisaka Minami, Shinya Furukawa, Teruki Miyake, Keisho Kurokawa, Yasuhiro Sasaki, Masayuki Nakaishi, Kensuke Nagamatsu, Hiroka Yamago, Naozumi Shibata, Yoichi Hiasa, Bunzo Matsuura   +10 more
wiley   +1 more source

Immunosuppressive Treatments and Risk Factors Associated with Non-Response to Hepatitis B Vaccination: A Cohort Study. [PDF]

Vaccines (Basel)
Padilla-Matas R, Salguero-Cano V, Soler-Iborte E, Baca-Hidalgo J, Pérez-Dionisio M, Gutiérrez-Linares S, Guerrero-Fernández de Alba I, Valero-Ubierna MDC, Fernández-Prada M, Rivera-Izquierdo M.   +9 more
europepmc   +1 more source

Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus‐Associated Hepatocyte Remodeling and Hepatocellular Carcinoma

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
ABSTRACT Background Hepatitis B virus (HBV)‐related liver cancer is the third most common cause of cancer‐related death globally. Hepatocyte remodeling, also known as hepatocyte transformation and immortalization, and hepatocellular carcinoma (HCC), are brought on by persistent inflammation caused by HBV in the host hepatocytes.
Adane Adugna, Gashaw Azanaw Amare, Mohammed Jemal   +2 more
wiley   +1 more source

Altered Circulating Cytokine Profile Among mRNA‐Vaccinated Young Adults: A Year‐Long Follow‐Up Study

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
ABSTRACT Objectives This longitudinal study aimed to assess the impact of COVID‐19 vaccination on cytokine profile. Methods A total of 84 Saudi subjects (57.1% females) with mean age of 27.2 ± 12.3 participated in this longitudinal study. Anthropometric data and fasting blood samples were obtained at baseline and after final vaccination, with an ...
Amani Alghamdi, Syed Danish Hussain, Kaiser Wani, Shaun Sabico, Abdullah M. Alnaami, Osama Emam Amer, Nasser M. Al‐Daghri   +6 more
wiley   +1 more source

Global burden of vaccine-associated kidney injury using an international pharmacovigilance database. [PDF]

Sci Rep
Hwang HS, Lee H, Yoon SY, Kim JS, Jeong K, Kronbichler A, Kim HJ, Kim MS, Rahmati M, Shin JY, Choi A, Shin JI, Lee J, Yon DK.   +13 more
europepmc   +1 more source

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This study investigates the risk of serious infections (SIs) in patients treated with biologic or targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in Qatar. Out of 1092 patients, 86 (7.9%) experienced SIs, with adalimumab and infliximab associated with higher SI rates.
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal, Ali S. Omrani, Muna Al Maslamani, Abdullatif Al‐Khal   +12 more
wiley   +1 more source

A Multiplex Bead Serology Panel For Vaccine-Preventable Diseases Using Dried Blood Spots. [PDF]

Risk Manag Healthc Policy
Olivo PD, Ghatak S, Rasch R.
europepmc   +1 more source

Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
Immune checkpoint molecules are today's leading targets for immunotherapy, especially in the field of cancer. This review summarizes the most important and recent advances in this field and in different types of cancer. ABSTRACT Background Today, treating cancer patients with monoclonal antibodies (mAbs), by targeting immune checkpoints, is one of the ...
Erfan Rezazadeh‐Gavgani, Reza Majidazar, Parisa Lotfinejad, Tohid Kazemi, Ali Shamekh   +4 more
wiley   +1 more source

Rapid immunization effects of a new type of 60 μg hepatitis B vaccine compared with traditional 20 μg hepatitis B vaccines in adults. [PDF]

Hum Vaccin Immunother, 2016
Wang H, Cai B, Rao D, Liu M, Li Y, Liang X, Cui F, Zhang G, Wang F, Pang X, Nie L, Qiu Q, Wu J, Li L, Huang F, Zhang W.   +15 more
europepmc   +1 more source

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Introduction Ruxolitinib was the first JAK2 inhibitor approved for the treatment of primary and secondary myelofibrosis. It is currently used worldwide as first‐line therapy for advanced disease (intermediate‐2 and high‐risk) and is effective in polycythaemia vera (PV) and essential thrombocythaemia (ET), but not funded for this indication in ...
Liesl A. Butler, Cecily Forsyth, Claire Harrison, Andrew C. Perkins   +3 more
wiley   +1 more source